Cancer Innovation最新文献

筛选
英文 中文
From Observational Biology to Functional and Computable Models of Living Systems 从观察生物学到生命系统的功能和可计算模型
IF 2
Cancer Innovation Pub Date : 2026-11-15 DOI: 10.1002/cai2.70090
Linjia Ji, Haili Qian
{"title":"From Observational Biology to Functional and Computable Models of Living Systems","authors":"Linjia Ji,&nbsp;Haili Qian","doi":"10.1002/cai2.70090","DOIUrl":"https://doi.org/10.1002/cai2.70090","url":null,"abstract":"<p>The proposed framework moves from fragmented biological evidence toward testable, computable life functions that describe how biological states evolve over time. A stepwise experimental approach progresses from molecular processes to unicellular and multicellular models, with tumor systems serving as models of pathological state transitions. The graphical image was Created with BioRender.com (Ji L. 2026; https://BioRender.com/zaxq2dd).\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 6","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149399983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk 双重PD-1/LAG-3阻断在乳腺癌中的作用:获益与风险
IF 2
Cancer Innovation Pub Date : 2026-10-27 DOI: 10.1002/cai2.70088
Kaixiang Feng, Fanxiang Yin, Mengting Chen, Zongbi Yi
{"title":"Dual PD-1/LAG-3 Blockade in Breast Cancer: Navigating Benefit and Risk","authors":"Kaixiang Feng,&nbsp;Fanxiang Yin,&nbsp;Mengting Chen,&nbsp;Zongbi Yi","doi":"10.1002/cai2.70088","DOIUrl":"https://doi.org/10.1002/cai2.70088","url":null,"abstract":"&lt;p&gt;The addition of immune checkpoint inhibitors to neoadjuvant chemotherapy has reshaped the treatment landscape for early-stage triple-negative breast cancer (TNBC). However, for hormone receptor-positive, HER2-negative (HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;−&lt;/sup&gt;) breast cancer, the most common subtype, the benefits of immunotherapy have remained limited. The I-SPY2 trial, recently published in &lt;i&gt;JAMA Oncology&lt;/i&gt;, evaluated the combination of the anti-PD-1 antibody cemiplimab and the anti-LAG-3 antibody fianlimab (the PCF regimen) in early-stage high-risk HER2-negative breast cancer [&lt;span&gt;1&lt;/span&gt;]. The results showed remarkable efficacy alongside safety concerns that warrant careful consideration.&lt;/p&gt;&lt;p&gt;In this adaptively randomized phase 2 trial, 76 evaluable patients were stratified by standard biomarker subtypes, including 40 with HR&lt;sup&gt;+&lt;/sup&gt;/HER2&lt;sup&gt;−&lt;/sup&gt; disease and 36 with TNBC. 350 patients served as historical controls. The primary efficacy endpoint was the pathologic complete response (pCR) rate after completion of neoadjuvant therapy. Overall, the estimated pCR rate of the PCF regimen reached 44% (95% confidence interval [CI], 34%–53%), more than doubling the 21% (95% CI, 17%–25%) observed in the historical control arm, meeting I-SPY2′s prespecified graduation criteria across the evaluated biomarker signatures. Notably, in HR&lt;sup&gt;+&lt;/sup&gt; /HER2&lt;sup&gt;−&lt;/sup&gt; disease, a subtype traditionally considered immunologically “cold,” the pCR rate increased from 14% (95% CI, 9%–19%) to 36% (95% CI, 23%–49%). These foundings are encouraging but should be interpreted cautiously. The subtype analyses exploratory without multiplicity adjustment, and I-SPY2 was not designed for formal interaction testing. Given the broad confidence intervals, confirmation of these benefits in adequately powered trials is required.&lt;/p&gt;&lt;p&gt;The biomarker findings were notable. Among HR&lt;sup&gt;+&lt;/sup&gt; /HER2&lt;sup&gt;−&lt;/sup&gt; patients with ImPrint-positive tumors, the pCR rate reached 91%, compared with only 28% among those with ImPrint-negative tumors. In TNBC, the corresponding rates were 83% and 28%, respectively [&lt;span&gt;1, 2&lt;/span&gt;]. Collectively, these data suggest that dual PD-1/LAG-3 blockade has potent biological activity in breast cancer, although prospective validation is still required. The biological rationale for this approach is illustrated in Figure 1. PD-1 and LAG-3 are non-redundant inhibitory checkpoints frequently co-expressed on exhausted CD8&lt;sup&gt;+&lt;/sup&gt; tumor-infiltrating lymphocytes (TILs). Co-blockade relieves two independent brakes, promoting stem-like CD8&lt;sup&gt;+&lt;/sup&gt; T cell expansion and restoring antitumor cytotoxicity.&lt;/p&gt;&lt;p&gt;Beyond breast cancer, the PD-1/LAG-3 combination has shown promise across multiple tumor types. In melanoma, the fixed-dose combination of relatlimab and nivolumab has been approved, establishing the clinical value of this dual blockade strategy [&lt;span&gt;3&lt;/span&gt;]. In recurrent glioblastoma, a phase 1 trial demonstrated a 12-month overall su","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70088","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert Consensus on the Standardized Diagnosis, Treatment, and Management of Cancer in High-Altitude Regions of China 中国高海拔地区肿瘤规范化诊断、治疗和管理专家共识。
IF 2
Cancer Innovation Pub Date : 2026-10-19 DOI: 10.1002/cai2.70084
Yiqun Li, Feng Li, Xiaorong Bai, Yan Li, Chengyun Bai, Qiaomei Chang, Cuiping Guo, Ji Di, Qiuxia Dong, Mengting Da, Zhongcheng Li, Zhen Liu, Hongxia Liang, Yushuang Luo, Dengfeng Ren, Pengjie Yu, Rui Ma, Miaozhou Wang, Xueshan Zhao, Fuxing Zhao, Guoshuang Shen, Zhiping Feng, Hao Wang, Shengtao Zhou, Wenqiang Wei, Shanshan Chen, Lin Wang, Feng Du,  Tseyang, Haifeng Xu, Xiaoling Ling, Gang Xu, Wei Guo, Yulan Zhao, Die Sang, Huachao Feng,  Deqingwangmu,  Gesangdeji,  Basangdunzhu,  Bianbazhaxi, Yixin Guo, Xinlong Tao, Guohui Bai, Wanpeng Yang, Hanhuan Luo, Yanming Lei,  Cidanwangjiu, Fei Ma, Dong Wu, Jiuda Zhao
{"title":"Expert Consensus on the Standardized Diagnosis, Treatment, and Management of Cancer in High-Altitude Regions of China","authors":"Yiqun Li,&nbsp;Feng Li,&nbsp;Xiaorong Bai,&nbsp;Yan Li,&nbsp;Chengyun Bai,&nbsp;Qiaomei Chang,&nbsp;Cuiping Guo,&nbsp;Ji Di,&nbsp;Qiuxia Dong,&nbsp;Mengting Da,&nbsp;Zhongcheng Li,&nbsp;Zhen Liu,&nbsp;Hongxia Liang,&nbsp;Yushuang Luo,&nbsp;Dengfeng Ren,&nbsp;Pengjie Yu,&nbsp;Rui Ma,&nbsp;Miaozhou Wang,&nbsp;Xueshan Zhao,&nbsp;Fuxing Zhao,&nbsp;Guoshuang Shen,&nbsp;Zhiping Feng,&nbsp;Hao Wang,&nbsp;Shengtao Zhou,&nbsp;Wenqiang Wei,&nbsp;Shanshan Chen,&nbsp;Lin Wang,&nbsp;Feng Du,&nbsp; Tseyang,&nbsp;Haifeng Xu,&nbsp;Xiaoling Ling,&nbsp;Gang Xu,&nbsp;Wei Guo,&nbsp;Yulan Zhao,&nbsp;Die Sang,&nbsp;Huachao Feng,&nbsp; Deqingwangmu,&nbsp; Gesangdeji,&nbsp; Basangdunzhu,&nbsp; Bianbazhaxi,&nbsp;Yixin Guo,&nbsp;Xinlong Tao,&nbsp;Guohui Bai,&nbsp;Wanpeng Yang,&nbsp;Hanhuan Luo,&nbsp;Yanming Lei,&nbsp; Cidanwangjiu,&nbsp;Fei Ma,&nbsp;Dong Wu,&nbsp;Jiuda Zhao","doi":"10.1002/cai2.70084","DOIUrl":"10.1002/cai2.70084","url":null,"abstract":"<p>Cancer has become one of the major diseases threatening the health of the Chinese population. The incidence of cancer in high-altitude regions of China is equally concerning. However, due to the unique geographical environment, population, and economic factors in high-altitude regions, there is an urgent need for a consensus on cancer prevention and management tailored to real-world clinical practice. To promote and standardize the diagnosis and treatment of cancer in high-altitude regions, under the leadership of the Breast Cancer Expert Committee of the National Cancer Quality Control Center and the Cancer Prevention and Treatment Committee of the Healthy China Research Center, experts in the field of high-altitude medicine were convened to jointly formulate the “Expert Consensus on the Standardized Diagnosis, Treatment, and Management of Cancer in High-Altitude Regions of China.” This consensus serves as a reference for clinicians in high-altitude regions.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149229753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management KRAS g12c突变型非小细胞肺癌的分子机制和治疗进展:以机制为导向的纵向管理
IF 2
Cancer Innovation Pub Date : 2026-10-15 DOI: 10.1002/cai2.70082
Haiying Wang, Hanxiao Chen, Sheng Li, Jun Zhao
{"title":"Molecular Mechanisms and Therapeutic Advances in KRAS G12C-Mutant Non-Small Cell Lung Cancer: Toward Mechanism-Guided Longitudinal Management","authors":"Haiying Wang,&nbsp;Hanxiao Chen,&nbsp;Sheng Li,&nbsp;Jun Zhao","doi":"10.1002/cai2.70082","DOIUrl":"https://doi.org/10.1002/cai2.70082","url":null,"abstract":"<p>KRAS G12C-mutant non-small cell lung cancer (NSCLC) has become a clinically actionable molecular subtype. Discovery of the switch-II pocket enabled the development of covalent KRAS G12C(OFF)-state inhibitors, transforming a historically “undruggable” target into a therapeutic vulnerability. Drugging KRAS, however, proved to be a problem of chemistry, whereas sustaining its inhibition has proved to be a problem of biology. KRAS G12C-mutant NSCLC is biologically heterogeneous, and the magnitude and durability of clinical benefit are shaped by co-mutations, the tumor microenvironment, brain metastases status, pharmacologic differences between agents, and the dynamic evolution of resistance. Randomized trials have demonstrated that sotorasib and adagrasib improve progression-free survival (PFS) and objective response rates (ORR) over docetaxel in previously treated disease, yet these gains have not translated consistently into a definitive overall survival (OS) advantage. This review synthesizes the epidemiology, molecular biology, diagnostic strategies, first- and later-line treatment evidence, resistance mechanisms, and emerging KRAS/RAS-directed approaches. We distinguish randomized or guideline-supported practice from early-phase and translational signals, and propose an implementable framework that combines PD-L1, tumor mutational burden, STK11/KEAP1/TP53 status, TTF-1 expression, brain metastases, and circulating tumor DNA (ctDNA) for risk stratification and mechanism-guided management. At disease progression, oligoprogression should be distinguished from systemic progression, and tissue re-biopsy together with plasma profiling should be considered when feasible. In China, several domestically developed KRAS G12C inhibitors have been approved, and reimbursement coverage is expanding; the cost of molecular testing, uneven institutional access, regional disparities and limited confirmatory and real-world evidence nonetheless continue to constrain implementation. Future priorities include randomized first-line comparisons, biomarker-defined combination strategies, improved central nervous system activity and mechanism-matched treatment after resistance.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measure of Innovation: From Clinical Questions to Actionable Evidence 创新的衡量:从临床问题到可操作的证据。
IF 2
Cancer Innovation Pub Date : 2026-10-14 DOI: 10.1002/cai2.70086
Shouzheng Wang, Fei Ma
{"title":"Measure of Innovation: From Clinical Questions to Actionable Evidence","authors":"Shouzheng Wang,&nbsp;Fei Ma","doi":"10.1002/cai2.70086","DOIUrl":"10.1002/cai2.70086","url":null,"abstract":"&lt;p&gt;Anticancer drug development has entered an age of abundance, but also one of unfinished promises. New targets, mechanisms, therapeutic agents, and treatment modalities are emerging at a remarkable pace. However, their scientific promise does not always translate into durable clinical benefits. Many patients still experience inadequate responses, treatment-related toxicities, or limited treatment options after disease progression, while clinically important patient subgroups remain underserved by current care. The clinical relevance of a development program therefore does not begin with how novel an intervention appears, but with the unmet need it seeks to address in a defined patient population.&lt;/p&gt;&lt;p&gt;Novelty has its allure. A first-in-class agent may open a field or reveal previously inaccessible vulnerabilities. However, scientific distinction and clinical value are not the same achievement. First-in-class status marks innovation but does not, by itself, demonstrate added benefit for patients [&lt;span&gt;1&lt;/span&gt;]. Drug development begins to matter when scientific possibility is directed toward a clinical problem worth solving.&lt;/p&gt;&lt;p&gt;A meaningful development program begins with a question that matters to patients. Why does an effective therapy fail too soon? Why does a particular subgroup derive little benefit? Can efficacy be preserved with less toxicity or recovered once resistance appears? Such questions give direction to discovery and determine what evidence will ultimately matter.&lt;/p&gt;&lt;p&gt;The challenge lies in turning a clinical problem into a testable therapeutic hypothesis. A detectable molecular alteration may suggest a target, but does not make that target clinically actionable. A mechanistically appealing combination may justify investigation, but does not establish synergy. A new modality may broaden what is technically possible without yet indicating whom it should treat or whether it improves the balance of benefit and harm.&lt;/p&gt;&lt;p&gt;Therefore, a more useful discipline would be to ask what uncertainty must be reduced before a clinical decision can reasonably change. That uncertainty may involve patient selection, mechanism, resistance, dose, treatment sequence, or combination strategy. The question should come first. Technology and novelty should serve it.&lt;/p&gt;&lt;p&gt;Early clinical development is where biological possibility first faces clinical scrutiny. Mechanism, exposure, pharmacodynamic effects, safety, tolerability, and preliminary antitumor activity should be considered concurrently rather than as isolated signals.&lt;/p&gt;&lt;p&gt;The phase I development of pyrotinib in human epidermal growth factor receptor 2 -positive metastatic breast cancer illustrates this approach. Dose escalation, pharmacokinetics, safety, antitumor activity, and predictive biomarkers were all evaluated within the same clinical framework, with next-generation sequencing performed on circulating tumor DNA and tumor tissue [&lt;span&gt;2&lt;/span&gt;]. The study established a maximum to","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13662520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanoprobe-Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma 纳米探针在视网膜母细胞瘤中的精确成像和全景边界划定。
IF 2
Cancer Innovation Pub Date : 2026-10-11 DOI: 10.1002/cai2.70083
Xuefei He, Precious Amarachi Ikwuagwu, Wenjing Pang, Aomen Chen, Lingchao Xiang, Feng Chen, Chen Xu, Aiguo Wu
{"title":"Nanoprobe-Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma","authors":"Xuefei He,&nbsp;Precious Amarachi Ikwuagwu,&nbsp;Wenjing Pang,&nbsp;Aomen Chen,&nbsp;Lingchao Xiang,&nbsp;Feng Chen,&nbsp;Chen Xu,&nbsp;Aiguo Wu","doi":"10.1002/cai2.70083","DOIUrl":"10.1002/cai2.70083","url":null,"abstract":"<p>Retinoblastoma is the most common primary intraocular malignancy in children. Its prognosis depends critically on accurate delineation of the tumor and its margins, early detection of small lesions, and timely monitoring of therapeutic response. Traditional single-modality imaging techniques are inherently constrained by trade-offs among spatial resolution, molecular sensitivity, and dynamic imaging capability, making them insufficient for the demands of precision diagnosis and treatment. In recent years, nanomedicine-based imaging strategies have emerged as promising approaches to overcome these limitations. Through rational design of nanoprobes with tunable physicochemical properties, active targeting capabilities, and integrated multimodal signaling, researchers have achieved more comprehensive visualization and diagnostic evaluation of retinoblastoma lesions. In this review, we systematically summarize the major imaging modalities applied to retinoblastoma, including optical imaging, ultrasound (US), magnetic resonance imaging (MRI), and photoacoustic imaging (PAI). Subsequently, the corresponding imaging probes and targeting strategies were discussed, which were developed to enhance the imaging contrast and improve the spatiotemporal resolution of tumor visualization. Furthermore, we highlight the emerging role of artificial intelligence (AI) in the rational design of high-performance imaging nanoprobes and in multimodal image analysis, emphasizing its potential to enable quantitative tumor and boundary delineation. Finally, we outline the key challenges that must be addressed to advance the clinical translation of nanoprobes, including the identification of novel targeting strategies, AI-assisted image analysis, the development of models that more accurately recapitulate the human ocular microenvironment, and the application of new biocompatible materials. Overall, this review aims to provide comprehensive and insightful guidance for the development of next-generation nanoprobes for the precise visualization and boundary delineation of retinoblastoma.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Not Whether, but in Whom: Reframing Antibody–Drug Conjugate Sequencing in Metastatic Breast Cancer 不是是否,而是在谁身上:重新构建转移性乳腺癌的抗体-药物偶联测序
IF 2
Cancer Innovation Pub Date : 2026-10-10 DOI: 10.1002/cai2.70085
Armando Orlandi
{"title":"Not Whether, but in Whom: Reframing Antibody–Drug Conjugate Sequencing in Metastatic Breast Cancer","authors":"Armando Orlandi","doi":"10.1002/cai2.70085","DOIUrl":"https://doi.org/10.1002/cai2.70085","url":null,"abstract":"<p>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149146122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Performance of Covidence's Artificial Intelligence-Based Screening Function in Cancer Systematic Reviews 评估基于covid的人工智能筛查功能在癌症系统评价中的表现
IF 2
Cancer Innovation Pub Date : 2026-09-28 DOI: 10.1002/cai2.70077
Ashirbani Saha, Xiaomei Yao, Sharan Saravanan, Aditya Misra, Ashley Low, Samya Ali, Mariam Abdelmalek, Shakil Ahmed, Sussman Jonathan
{"title":"Evaluating the Performance of Covidence's Artificial Intelligence-Based Screening Function in Cancer Systematic Reviews","authors":"Ashirbani Saha,&nbsp;Xiaomei Yao,&nbsp;Sharan Saravanan,&nbsp;Aditya Misra,&nbsp;Ashley Low,&nbsp;Samya Ali,&nbsp;Mariam Abdelmalek,&nbsp;Shakil Ahmed,&nbsp;Sussman Jonathan","doi":"10.1002/cai2.70077","DOIUrl":"https://doi.org/10.1002/cai2.70077","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Systematic reviews (SRs), often conducted for evidence synthesis, require extensive multistage screening, with Stage-I title/abstract screening being especially time consuming. Covidence systematic review software, a widely used SR platform, has offered artificial intelligence (AI)-assisted Stage-I screening function since 2022. However, this function's performance has not yet been formally compared across heterogeneous, large-scale oncology-focused SRs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We selected two completed SRs conducted by the Program in Evidence-based Care (PEBC), Ontario, Canada. The first SR (Axilla-BC, &lt;i&gt;N&lt;/i&gt; = 8774) supported a clinical practice guideline in breast cancer and the second SR (PET-utility, &lt;i&gt;N&lt;/i&gt; = 7267) informed the provincial Positron Emission Tomography (PET) steering committee in Ontario. Using each SR, we conducted a simulation-based study by drawing subsets of 500, 1000, and 2000 articles and running 30, 30, and 10 simulation trials, respectively, to emulate Covidence's AI-assisted Stage-I screening. For each trial, we calculated the workload and time savings at 95% and 100% sensitivity for relevant articles and at 100% sensitivity for finally included articles as primary outcomes. Secondary outcomes comprised missed finally included articles at 95% sensitivity for relevant articles. Wilcoxon rank-sum tests were used to compare outcomes between these two SRs.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;When pooling all subset sizes and the &lt;i&gt;N&lt;/i&gt; = 1000 subsets, workload savings at 95% sensitivity were significantly higher for Axilla-BC than for PET-utility (median = 37.4% &lt;i&gt;vs.&lt;/i&gt; 26.2%, &lt;i&gt;W&lt;/i&gt; = 3156.5, &lt;i&gt;p&lt;/i&gt; = 0.003 and median = 38.3% &lt;i&gt;vs.&lt;/i&gt; 20.5%, &lt;i&gt;W&lt;/i&gt; = 641.0, &lt;i&gt;p&lt;/i&gt; = 0.005, respectively). Corresponding time savings were also significantly higher for Axilla-BC (median = 6.0 &lt;i&gt;vs.&lt;/i&gt; 4.2 h, &lt;i&gt;W&lt;/i&gt; = 3089.5, &lt;i&gt;p&lt;/i&gt; = 0.008 and median = 9.6 &lt;i&gt;vs.&lt;/i&gt; 5.1 h, &lt;i&gt;W&lt;/i&gt; = 639.0, &lt;i&gt;p&lt;/i&gt; = 0.005). In Axilla-BC, 20% of the 70 trials missed a total of 18 finally included articles, but only one PET-utility trial missed one article.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In two large oncology-SRs, Covidence's AI-assisted Stage-I screening function demonstrated meaningful potential to reduce reviewer workload and screening time. Nonetheless, Covidence's performance varied notably between reviews, suggesting a possible association between the results and the characteristics of the SR, including topic, methodological complexity, re","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 5","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cai2.70077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy 放射性碘难治性分化甲状腺癌:定义、分子机制和精准治疗进展。
IF 2
Cancer Innovation Pub Date : 2026-08-26 DOI: 10.1002/cai2.70078
Yamin Li, Zuoxiang He
{"title":"Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy","authors":"Yamin Li,&nbsp;Zuoxiang He","doi":"10.1002/cai2.70078","DOIUrl":"10.1002/cai2.70078","url":null,"abstract":"<p>Radioiodine-refractory differentiated thyroid cancer, defined by loss of responsiveness to ¹³¹I therapy or by heterogeneous iodine uptake, accounts for the majority of thyroid cancer-related deaths; 10-year survival is approximately 10% with distant metastases. Its definition is not uniform: the 2014 expert consensus and the 2015 American Thyroid Association guideline diverge on heterogeneous uptake and on progression despite substantial uptake, and the 2019 Martinique principles reframe these as risk-stratification triggers rather than absolute disqualifiers. Refractoriness reflects mitogen-activated protein kinase-driven silencing of the sodium iodide symporter; <i>TERT</i> promoter mutations, often co-occurring with <i>BRAF</i> V600E, are associated with dedifferentiation. The therapeutic landscape has changed over the past decade: antiangiogenic multikinase inhibitors (lenvatinib, sorafenib, and cabozantinib) are established first- and second-line options; molecular profiling supports genotype-driven and tumor-agnostic treatment of <i>RET</i>, <i>NTRK</i>, and <i>ALK</i> fusions and <i>BRAF</i> V600E mutations; redifferentiation with MEK or combined BRAF/MEK inhibition can restore radioiodine uptake in selected patients, with responses that vary by molecular subtype; and immune checkpoint inhibitors benefit the rare microsatellite instability-high or mismatch repair-deficient subset. Most syntheses organize these options by molecular driver and evidence level, whereas the patient's experience of therapy (toxicity, disruption of daily life, decisional preferences) is acknowledged but seldom carried into recommendations. This review compares those definitions, appraises the evidence for each therapeutic class, defines where ¹²⁴I lesional dosimetry can refine treatment timing, and adds the patient dimension as an explicit third axis, operationalized through two tables: a patient-centered agent comparison and a scenario-specific decision matrix. The evidence supports, without yet establishing, early broad molecular profiling, a selective inhibitor where an actionable alteration is present, a multikinase backbone otherwise, and redifferentiation only where tested. Randomized evidence is distinguished throughout from expert opinion. Head-to-head comparisons and sequencing data remain limited; circulating tumor DNA and imaging-derived biomarkers, so far supported only by small cohorts, and adaptive trial designs are the most plausible routes forward. By making treatment burden as explicit as genotype and evidence level, the framework is intended to make treatment selection and shared decision-making more reproducible.</p>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148842707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Burden and Temporal Trends of Brain and Central Nervous System Tumors in Children and Adolescents: A Systematic Analysis for the Global Burden of Disease Study 2021 儿童和青少年脑和中枢神经系统肿瘤的全球负担和时间趋势:2021年全球疾病负担研究的系统分析
IF 2
Cancer Innovation Pub Date : 2026-08-23 DOI: 10.1002/cai2.70079
Zhaoyang Feng, Yu Su, Lin Yang, Kaiwen Deng, Jianmin Wang, Jiao Zhang, Fei Liu, Dongyang Wang, Yuyan Liang, Wei Wang, Xiaoguang Qiu, Tao Jiang, Yu Tian, Hailong Liu
{"title":"Global Burden and Temporal Trends of Brain and Central Nervous System Tumors in Children and Adolescents: A Systematic Analysis for the Global Burden of Disease Study 2021","authors":"Zhaoyang Feng,&nbsp;Yu Su,&nbsp;Lin Yang,&nbsp;Kaiwen Deng,&nbsp;Jianmin Wang,&nbsp;Jiao Zhang,&nbsp;Fei Liu,&nbsp;Dongyang Wang,&nbsp;Yuyan Liang,&nbsp;Wei Wang,&nbsp;Xiaoguang Qiu,&nbsp;Tao Jiang,&nbsp;Yu Tian,&nbsp;Hailong Liu","doi":"10.1002/cai2.70079","DOIUrl":"10.1002/cai2.70079","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Central nervous system (CNS) tumors pose major global health challenges. Previous studies often assessed all-age populations without focusing on children and adolescents. We analyzed the burden and temporal trends of CNS tumors among individuals aged &lt; 20 years from 1990 to 2021, with projections to 2036.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were obtained from the Global Burden of Disease Study 2021, including annual incidence, mortality, and disability-adjusted life years (DALYs) for brain and CNS tumors. Regions were classified by Socio-demographic Index (SDI) to examine associations between burden and development. Temporal trends were analyzed using the age-period-cohort (APC) model and future projections via the Bayesian APC model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2021, an estimated 40,534.53 (95% uncertainty interval [UI]: 33,345.94–49,609.04) new cases of brain and CNS tumors occurred worldwide. The global age-standardized incidence rate (ASIR) was 1.54 (95% UI: 1.27–1.88), and the death rate (ASDR) was 0.76 (0.61–0.93) per 100,000. High-SDI regions showed the highest ASIR and ASDR, while lower-SDI regions faced growing burdens. Mortality and DALYs improved most in Greenland, Serbia, and China. The APC model showed a mild global decline in incidence (<i>p</i> = 0.099) and significant mortality reduction (−1.16% annually, <i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Global CNS tumor burden declined but remains uneven. Enhanced prevention and healthcare access are needed, especially in low-SDI regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100212,"journal":{"name":"Cancer Innovation","volume":"5 4","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13499956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书